Original language | English (US) |
---|---|
Pages (from-to) | 2402-2404 |
Number of pages | 3 |
Journal | Leukemia |
Volume | 29 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2015 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. / Wenn, K.; Tomala, L.; Wilop, S.; Vankann, L.; Hasenbank, C.; Frank, O.; Hochhaus, A.; Giles, F. J.; Lange, T.; Müller, M. C.; Koschmieder, S.; Beier, F.; Ziegler, P.; Brümmendorf, T. H.
In: Leukemia, Vol. 29, No. 12, 01.12.2015, p. 2402-2404.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib
AU - Wenn, K.
AU - Tomala, L.
AU - Wilop, S.
AU - Vankann, L.
AU - Hasenbank, C.
AU - Frank, O.
AU - Hochhaus, A.
AU - Giles, F. J.
AU - Lange, T.
AU - Müller, M. C.
AU - Koschmieder, S.
AU - Beier, F.
AU - Ziegler, P.
AU - Brümmendorf, T. H.
N1 - Funding Information: honoraria from Novartis, BMS, Pfizer and Ariad and research funding from Novartis. MCM receives honoraria and research funding from Ariad, BMS and Novartis. SK is a consultant and member on an entity’s Board of Directors or advisory committees for Novartis and receives honoraria and research funding by Novartis. THB is a consultant and receives honoraria from Ariad, BMS, Novartis and Pfizer, he holds patents and royalties at Novartis and receives research funding from Novartis. The remaining authors declare no conflict of interest. Funding Information: SW has an advisory role for Astellas, Merck and Janssen, he receives research funding from Enceladus and travel is sponsored by Merck and Celgene. OF is a Novartis employee. AH receives research funding from Novartis, BMS, Ariad, Pfizer and MSD. FJG is a consultant for Novartis and receives research funding by Novartis. TL receives
PY - 2015/12/1
Y1 - 2015/12/1
UR - http://www.scopus.com/inward/record.url?scp=84951569512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951569512&partnerID=8YFLogxK
U2 - 10.1038/leu.2015.245
DO - 10.1038/leu.2015.245
M3 - Letter
C2 - 26369986
AN - SCOPUS:84951569512
VL - 29
SP - 2402
EP - 2404
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 12
ER -